Iza-bren Clinical Trials

3 actively recruiting trials across 3 locations

No change since June 2026

Also known as: BL-B01D1, BMS-986507, Izalontamab brengitecan

Pipeline

Phase 2/3: 3

Top Sponsors

Bristol-Myers Squibb3

Indications

Cancer3
Breast Neoplasms1
Urothelial Cancer1
Lung Cancer1
Breast Cancer1

Gilbert, Arizona1 trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Local Institution - 0167

Phase 2/3

Hot Springs, Arkansas1 trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0303

Phase 2/3

Irvine, California1 trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.